Vifor Pharma announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease. Vamifeport, developed by Vifor Pharma, is a novel oral ferroportin inhibitor investigated for treatment of diseases characterized by ineffective production of red blood cells and iron overload, including SCD and beta-thalassemia. It has been granted orphan drug designation from both the U.S.
- Read more about First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/first-patient-enrolled-in-phase-iia-study-of-vamifeport-in-patients-with-sickle-cell-disease
No comments:
Post a Comment